Dr. Saad Discusses the Benefit of Radium-223 in Patients with mCRPC
Fred Saad, MD, FRCS, University of Montreal, discusses the benefit of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Fred Saad, MD, FRCS, professor, Department of Surgery, University of Montreal, discusses the benefit of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Saad says the full benefit is a 30% reduction risk of death; he and his colleagues realized that patients who were not able to receive the full 6 cycles seemed to benefit less. He adds that PSA is not a good reflection of activity, while alkaline phosphatase seems to be a much better marker of response activity. Patients who are given a lower dose of alkaline phosphatase have a significantly better survival than those who are not, so a follow-up for patients receiving the radium-223 is recommended.
One of the next steps for future trials would be to confirm the added benefit of combining the agent with other therapies, such as abiraterone and enzalutamide, concludes Saad.
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
Participants Discuss Frontline Immunotherapy Followed by ADC for Metastatic Cervical Cancer
December 19th 2024During a Case-Based Roundtable® event, Ramez N. Eskander, MD, and participants discussed first and second-line therapy decisions for a patient with PD-L1–positive cervical cancer in the frontline metastatic setting.
Read More
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL
December 18th 2024During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Read More
